---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036170"
form_type: "8-K"
ticker: "LFMD"
cik: "0000948320"
company_name: "LifeMD, Inc."
filed_at: "2026-08-05T20:10:53+00:00"
generated_at: "2026-08-05T20:12:36.574152+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LifeMD Q2 revenue $47.3M, adjusted EBITDA loss $3.5M; revises FY2026 guidance

## Summary
- Revenue $47.3M within guidance; adjusted EBITDA loss $3.5M improved 21% sequentially but below guided range.
- Gross margin expanded ~280 bps YoY to ~89%; total active subscribers up 20% YoY to ~356k.
- Weight management subscribers ~108k; ~95% of new weight patients start on branded GLP-1 therapies.
- Launched telehealth co-marketing with Halozyme's Antares for XYOSTED; expects $2-3M net launch costs in 2026.
- Revises FY2026 guidance: revenue $205.5M-$212.5M, adjusted EBITDA -$6M to breakeven; expects positive adjusted EBITDA in H2 2026.

## SEC filing metadata
- accession: 0001493152-26-036170
- form_type: 8-K
- ticker: LFMD
- cik: 0000948320
- company_name: LifeMD, Inc.
- filed_at: 2026-08-05T20:10:53+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/948320/000149315226036170/0001493152-26-036170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/948320/000149315226036170/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036170
- JSON: https://secwatch.observer/filing/0001493152-26-036170.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.